## Yasuko Iwakiri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1452669/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Hyperdynamic Circulation of Chronic Liver Diseases: From the Patient to the Molecule. Hepatology, 2006, 43, S121-S131.	7.3	523
2	Vascular endothelial dysfunction in cirrhosis. Journal of Hepatology, 2007, 46, 927-934.	3.7	273
3	Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions. Journal of Hepatology, 2014, 61, 912-924.	3.7	246
4	Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19777-19782.	7.1	232
5	Pathophysiology of Portal Hypertension. Clinics in Liver Disease, 2014, 18, 281-291.	2.1	208
6	Nitric oxide in liver diseases. Trends in Pharmacological Sciences, 2015, 36, 524-536.	8.7	193
7	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. American Journal of Physiology - Renal Physiology, 2006, 290, G980-G987.	3.4	176
8	Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver International, 2012, 32, 199-213.	3.9	156
9	Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release. Journal of Biological Chemistry, 2004, 279, 30349-30357.	3.4	119
10	Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1365-1374.	3.3	103
11	The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 733-749.	4.5	97
12	Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1139-1161.	4.5	91
13	Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clinical and Molecular Hepatology, 2015, 21, 319.	8.9	84
14	The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International, 2018, 12, 1-10.	4.2	81
15	Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology, 2003, 125, 1452-1461.	1.3	79
16	Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. American Journal of Physiology - Renal Physiology, 2002, 283, G1074-G1081.	3.4	77
17	Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2084-H2090.	3.2	75
18	A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. Journal of Hepatology, 2003, 39, 940-946.	3.7	75

YASUKO IWAKIRI

#	Article	IF	CITATIONS
19	The lymphatic vascular system in liver diseases: its role in ascites formation. Clinical and Molecular Hepatology, 2013, 19, 99.	8.9	70
20	The Molecules. Journal of Clinical Gastroenterology, 2007, 41, S288-S294.	2.2	69
21	An endoplasmic reticulum protein, Nogoâ€B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology, 2017, 65, 1720-1734.	7.3	68
22	Biology of portal hypertension. Hepatology International, 2018, 12, 11-23.	4.2	67
23	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology, 2021, 75, 647-658.	3.7	67
24	Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. Journal of Hepatology, 2015, 62, 325-331.	3.7	65
25	Reticulon 4 Is Necessary for Endoplasmic Reticulum Tubulation, STIM1-Orai1 Coupling, and Store-operated Calcium Entry. Journal of Biological Chemistry, 2014, 289, 9380-9395.	3.4	62
26	Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Reports, 2021, 3, 100316.	4.9	61
27	O-GlcNAc transferase suppresses necroptosis and liver fibrosis. JCI Insight, 2019, 4, .	5.0	60
28	Development of Small Diameter Nanofiber Tissue Engineered Arterial Grafts. PLoS ONE, 2015, 10, e0120328.	2.5	56
29	Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosis. Hepatology, 2011, 53, 1306-1315.	7.3	52
30	Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. FASEB Journal, 2015, 29, 3436-3445.	0.5	50
31	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. Journal of Hepatology, 2006, 44, 886-893.	3.7	47
32	Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats. Gastroenterology, 2021, 160, 1315-1329.e13.	1.3	45
33	Lymphatics in the liver. Current Opinion in Immunology, 2018, 53, 137-142.	5.5	41
34	Covidâ€19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatology Communications, 2022, 6, 255-269.	4.3	41
35	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. Journal of Cellular and Molecular Medicine, 2012, 16, 1125-1133.	3.6	40
36	Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 535-549.e14.	4.5	32

YASUKO IWAKIRI

#	Article	IF	CITATIONS
37	S-nitrosylation of proteins: A new insight into endothelial cell function regulated by eNOS-derived NO. Nitric Oxide - Biology and Chemistry, 2011, 25, 95-101.	2.7	31
38	Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice. Hepatology, 2013, 57, 1992-2003.	7.3	31
39	Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease. Journal of Hepatology, 2021, 75, 377-386.	3.7	31
40	Proteomic Identification of S-Nitrosylated Golgi Proteins: New Insights into Endothelial Cell Regulation by eNOS-Derived NO. PLoS ONE, 2012, 7, e31564.	2.5	25
41	Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. American Journal of Physiology - Renal Physiology, 2019, 317, G387-G397.	3.4	25
42	Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in Mice. American Journal of Pathology, 2013, 182, 786-795.	3.8	24
43	Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. Journal of Hepatology, 2020, 73, 1482-1495.	3.7	24
44	Pathological characteristics of liver sinusoidal thrombosis in COVIDâ€19 patients: A series of 43 cases. Hepatology Research, 2021, 51, 1000-1006.	3.4	24
45	Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1. American Journal of Pathology, 2011, 179, 2990-2999.	3.8	23
46	Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver. Journal of Controlled Release, 2019, 304, 259-267.	9.9	23
47	The lymphatic system: A new frontier in hepatology. Hepatology, 2016, 64, 706-707.	7.3	21
48	Hepatic lymphatic vascular system in health and disease. Journal of Hepatology, 2022, 77, 206-218.	3.7	19
49	Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatology Research, 2007, 37, 58-67.	3.4	18
50	A role of miR-33 for cell cycle progression and cell proliferation. Cell Cycle, 2012, 11, 1057-1057.	2.6	14
51	Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery, 2018, 25, 1055-1065.	5.7	10
52	Is miRâ€21 a potent target for liver fibrosis?. Hepatology, 2018, 67, 2082-2084.	7.3	9
53	Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. Journal of Controlled Release, 2022, 341, 457-474.	9.9	8
54	Inhibition of high-fat diet–induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms. Journal of Biological Chemistry, 2022, 298, 101561.	3.4	7

YASUKO IWAKIRI

#	Article	IF	CITATIONS
55	Hepatic congestion leads to fibrosis: Findings in a newly developed murine model. Hepatology, 2015, 61, 428-430.	7.3	6
56	Endothelial Leukocyte Cell–Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulinâ€Like and Epidermal Growth Factor–Like Domains 1 Signaling in Liver Fibrosis. Hepatology, 2020, 72, 347-349.	7.3	6
57	Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model. Regenerative Medicine, 2017, 12, 929-938.	1.7	4
58	Pathophysiology of Portal Hypertension. , 2014, , 3-14.		4
59	Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats. Scientific Reports, 2018, 8, 17983.	3.3	3
60	The lymphatic system in alcohol-associated liver disease. Clinical and Molecular Hepatology, 2020, 26, 633-638.	8.9	3
61	Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?. Hepatology International, 2015, 9, 337-338.	4.2	2
62	The Systemic and Splanchnic Circulations. , 2011, , 305-321.		2
63	Alcohol and calcium make a potent cocktail. Journal of Physiology, 2017, 595, 3109-3110.	2.9	1
64	Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget, 2017, 8, 66426-66437.	1.8	1
65	Reply. Hepatology, 2017, 65, 2134-2134.	7.3	0
66	Reply. Hepatology, 2017, 66, 1702-1703.	7.3	0
67	Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 663-664.	4.5	0
68	Obituary for Roberto J. Groszmann—The Father of Portal Hypertension. Hepatology, 2021, 74, 1724-1726.	7.3	0